Dr. Reddy's Laboratories Ltd. · NSE:DRREDDY
Dr. Reddy's Laboratories — Investor Presentation (June 2012)
29 slides from Dr. Reddy's Laboratories's investor presentation, June 2012
Slide 1: The Dr. Reddy's Story
& Y Dr. REDDY'S The Dr. Reddy’s Story LIFE CRESEARCH.H O1P.&
Slide 2: Outline
Outline Our Purpose The journey so far: Key Milestones Dr. Reddy’s today Key Questions www.drreddys.com
Slide 3: Our Purpose
Our Purpose Purpose Providing affordable and innovative medicines for healthier lives www.drreddys.com
Slide 4: Our Values
Our Values In pursuit of OUL PULPOSE of providing affordable and innovative medicines for healthier lives, we will create an environment of innovation and learning while continually reaching for higher levels of excellence. Integrity and Transparenc We will uphold the highest standards of integrity
Slide 5: Outline
Outline Our Purpose The journey so far: Key Milestones Dr. Reddy’s today Key Questions www.drreddys.com
Slide 6: Taking the First Steps (1984-1990)
Key Milestones Taking the First Steps (1984-1990) Established by Dr K Anji Reddy with an initial capital outlay of Rs.25 lakhs 1984 Goes public with listing in Bombay Stock Exchange 1986 Enters international markets with exports of Methyldopa Obtains its first USFDA approval for Ibuprofen API 198
Slide 7: Expanding and Innovating (1991-1999)
Key Milestones Expanding and Innovating (1991-1999) Formulation exports to Russia commences 1991 1993 Establishes Dr. Reddy's Research Foundation. Drug Discovery program starts Dr. Reddy's Research Foundation files first patent in the US 1995 Becomes first Indian company to out-license an original
Slide 8: Growing Globally (2000- present)
Key Milestones Growing Globally (2000- present) Cheminor Drugs (A group company) merges with Dr. Reddy‘s 2000 Establishes Reddy US therapeutics in USA Becomes the first pharma company in Asia Pacific, outside of Japan, to list on NYSE 2001 Obtains 1st ever 180-day mkt. exclusivity for a generic
Slide 9: Growing Globally (2000- present)
Key Milestones Growing Globally (2000- present) GlaxoSmithKline and Dr. Reddy’s agrees to the sale of US Penicillin Facility and 2011 Products FUJIFILM and Dr. Reddy’s establishes an exclusive joint venture for developing, manufacturing and promoting generic drugs in Japan Launches Over-the-Count
Slide 10: Outline
Outline Our Purpose The journey so far: Key Milestones Dr. Reddy’s today Key Questions www.drreddys.com
Slide 11: Dr. Reddy's Today
Dr. Reddy’s Today Vertically integrated global pharmaceutical company from India Revenues of U.S. $ 2 bn* in FY2012 with a CAGR of ~ 20% over the last decade Strong portfolio of businesses, geographies and products Three business segments Pharmaceutical Services & Active Ingredients, Global
Slide 12: Dr. Reddy's Today: Infrastructure & Capabilities
Dr. Reddy’s Today Infrastructure & Capabilities Pharmaceutical Services & Global Generics Product Development Active Ingredients Integrated product 6 FDA-approved plants in 7 Formulation plants in India development capabilities that India (2 USFDA inspected) include API 1 Cytotoxic facility
Slide 13: Dr. Reddy's Today: Infrastructure & Capabilities
Dr. Reddy’s Today Infrastructure & Capabilities New Chemical Entities Biologics (NCEs) Biologics development Research in the areas of center metabolic, cardiovascular, GMP production anti-bacterials, and pain & E coli and mammalian cell inflammation. platforms www.drreddys.com
Slide 14: Our Businesses
Our Businesses Proprietary Products Pharmaceutical Global Generics • Focus on building Services & Active sustainable and profitable • Finished dosage businesses Ingredients in distribution-driven as well branded businesses as doctor-driven markets • Customers include generic • Efforts in Biosimilars
Slide 15: The Last 5 years
The Last 5 years Revenue ($ Mn) 2,021 1,639 1,509 1,481 1,241 FY08 FY09 FY10 FY11 FY12 Note: Adjusted for one time impacts www.drreddys.com
Slide 16: Recap - FY12 Global Generics
Recap - FY12 Global Generics ` 7,037 Crs (32% YoY growth) Europe `835 Crs (-1% gr) Russia & Other CIS `1,334 Crs (23% gr) US `3,175 Crs (67% gr) India `1,294 Crs (11% gr) Rest of World `399 Crs (19% gr) www.drreddys.com
Slide 17: Recap- FY12: Global Generics
Recap- FY12: Global Generics US $ Million Russia Rouble Million 62% 15% India ` Crs Europe € Mn -10% 11% www.drreddys.com 17
Slide 18: Recap- FY12: PSAI
Recap- FY12: PSAI Revenues ` Crs 21% www.drreddys.com
Slide 19: Recap FY12: API
Recap FY12: API ` 1,852 Crs (21% YoY growth) Europe `564 Crs (29% gr) North America `242 Crs (26% gr) India `359 Crs (37% gr) Rest of World `687 Crs (7% gr) www.drreddys.com
Slide 20: Recap FY12: CPS
Recap FY12:CPS ` 530 Crs (23% YoY growth) Europe `278 Crs (5% gr) North America `185 Crs (48% gr) Rest of World `67 Crs (67% gr) www.drreddys.com
Slide 21: Dr. Reddy's edge in the pharma space
Dr. Reddy’s edge in the pharma space Industry leading chemistry skills which has resulted in several niche product opportunities (eg: fondaparinux, fexofenadine-pseudoephedrine, omeprazole mg, lansoprazole) High vertical integration (~75% of APIs sourced internally) Amongst the leading pipeline in f
Slide 22: Outline
Outline Our Purpose The journey so far: Key Milestones What is Dr. Reddy’s today Key Questions www.drreddys.com
Slide 23: Key Questions
Key Questions 1. What are our aspirations for each business ? 2. Why do we believe we will succeed ? www.drreddys.com
Slide 24: What are our aspirations?
1. What are our aspirations? Improve depth in key Leadership markets through portfolio Global Generics position expansion and supply in key markets chain excellence Pharmaceutical Create compelling value Services for customers by Partner of & Active leveraging IP, technology Choice Ingredients and c
Slide 25: Why do we believe we will succeed?
2. Why do we believe we will succeed? Key markets Product Focus Supply chain delivery & excellence engine Depth Vertical integration with cost, technology & IP leverage www.drreddys.com
Slide 26: Top Brands - India
Top Brands - India OMEZ NISE STAMLO REDITUX OMEZ-DSR STAMLO BETA ATOCOR RAZO RAZO - D MINTOP www.drreddys.com
Slide 27: Commitment to Sustainability
Commitment to Sustainability Collective Actions – Our DNA of Sustainability OUR SUSTAINABILITY FRAMEWORK Providing Affordable and Innovative Medicines Environment management and Climate Change Being an Employer of Choice Product Responsibility Sustainable Sourcing Caring for Communities
Slide 28: Recent Recognitions
Recent Recognitions Dr Anji Reddy wins the ‘Executive of the Year’ award from Biopharma Singapore 2012 Award for Learning & Talent Initiative for ‘exhibiting visionary leadership, leading & Excellence 2nd STAR News HR & communicating change, building Leadership Awards at World HRD partnerships, and
Slide 29: Thank You
THANK THANK YOU www.drreddys.com
Dr. Reddy's Laboratories — Investor Presentation (June 2012) on 6ix